Molecular Residual Disease Precedes Disease-Free Survival Events by Months

Major Finding: Molecular residual disease (MRD) preceded death or clinical recurrence in the ADAURA trial by nearly 5 months. Concept: Longitudinal MRD monitoring may stratify risk for patients with EGFR-mutant non–small cell lung cancer (NSCLC) following resection.Impact: This post hoc analysis proposes the value of MRD to predict risk as well as patients that might benefit from therapy escalation.